top of page

Inflection Biosciences Announces Pre-clinical Data to be Presented at the ASH 2014 Annual Meeting

Dublin, Ireland, December 3rd, 2014 – Inflection Biosciences Ltd, a private company developing novel targeted small molecule therapeutics for the treatment of cancer, today announced that new data on IBL-202, a dual mechanism PIM/PI3 kinase inhibitor will be highlighted in a poster presentation at the 56th Annual Meeting of the American Society for Haematology (ASH), to be held December 6-9, 2014 in San Francisco, California.

The pre-clinical data was generated from a collaboration with Dr. Oliver Giles Best of the Northern Blood Research Centre, Kolling Institute of Medical Research, University of Sydney, Australia, and a member of the CLL Australian Research Consortium (CLLARC), Sydney, Australia. The results show, for the first time, anti-cancer activity of combined PIM and PI3K inhibition by the unique dual acting compound in cells taken from patients with chronic lymphocytic leukemia.

The presentation (Abstract #4693) entitled, “Dual Inhibition of PIM and PI3-Kinase by IBL-202 is Highly Synergistic Compared to Mono-Molecular Inhibition and Represents a Novel Treatment Strategy for Chronic Lymphocytic Leukemia” will be made by Dr. Best on Monday December 8th from 6.00 pm - 8.00 pm during Session: 642. CLL: Therapy, excluding Transplantation: Poster III.

The abstract for the presentation made at the ASH Annual Meeting 2014 is available here.

About PIM/PI3 kinase inhibitors

The PI3K/AKT pathway is commonly activated in human cancer. Multiple small-molecule inhibitors have been developed to target PI3K/mTOR or AKT kinases, but the efficacy of these drugs is compromised by the stimulation of compensatory signaling pathways. One example of such compensatory pathways is that driven by PIM kinases, which produce parallel oncogenic signals to AKT and mTOR and share several downstream molecular targets. Therefore, combined inhibition of such activities in a single molecule might have the potential to achieve better clinical efficacy and prevent/suppress resistance in comparison with classical PI3K/AKT/mTOR inhibitors.

About Inflection Biosciences

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments were licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises a unique dual mechanism pan-PIM/PI3 kinase inhibitor program and a pan-PIM kinase inhibitor program, both in pre-clinical development. Data generated to date suggests potential application in a range of haematological malignancies and treatment resistant solid tumours. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit the Company’s website at


bottom of page